Osteogenon has an analgetic effect, improves well being, raises physical activity, reduces duration of fracture consolidation in patients with SO.
40 tablets
Pharmacological action:
Osteogenon - a drug that regulates calcium and phosphorus metabolism. The drug stimulates osteoblasts and inhibits osteoclasts, so that there is a restoration of balance between the processes of bone resorption and bone regeneration.
The preparation contains calcium in the form of hydroxyapatite, which not only improves the absorption of the drug in the gastrointestinal tract, but also prevents the development of hypercalcemia peak due to the gradual release of calcium ions. Calcium inhibits the synthesis of PTH hormone prevents bone resorption.
Phosphorus is a strengthening effect of calcium supplements on bone tissue, due to the ability to fix calcium in bone tissue and reduce its excretion by the kidneys.
The composition includes ossein local regulators of bone remodeling, osteocalcin, and type I collagen. Ossein stimulates bone formation and collagen synthesis, increases the number and activity preosteoblast, inhibits the formation of osteoclast precursors. The drug also increases the crystallization of the bone due to binding of calcium, and regulates the production of bone matrix.
The active ingredients of the drug after oral administration are absorbed in the duodenum and proximal small intestine.
Indications:
The drug is used for treatment of patients with diseases of the musculoskeletal system, including:
Dysplasia of the joints and connective tissue.
Primary and secondary osteoporosis of various genesis.
In the treatment of rachitic skeletal deformities and scoliosis.
The drug is also used in patients with fractures to accelerate consolidation.
In addition, the drug can be appointed during pregnancy and lactation, women suffering from disorders of calcium-phosphorus metabolism.
Mode of application:
The drug is intended for oral administration. Coated tablets, it is recommended to swallow whole without chewing or crushing with a little liquid. The drug is taken regardless of meals. The duration of treatment and the dose determines the physician individually for each patient.
Adults for the treatment of systemic osteoporosis usually prescribed 2-4 tablets of the drug 2 times a day. The duration of treatment is usually 6-12 months.
Adults with a broken bone usually prescribed 2 tablets of the drug 2-3 times a day. The duration of the drug is typically 3 months.
Adults with other indications usually prescribed 1 tablet 1-2 times a day. The duration of treatment is usually 3 months.
With prolonged use of the drug is recommended to control the level of calcium in the blood and urine.
Side effects:
The drug is generally well tolerated by patients. In a few cases, mainly in patients with increased individual sensitivity, noted the development of allergic reactions.
With prolonged use of the drug in some patients noted the development of hypercalcemia and hypercalciuria.
Contraindications:
Increased individual sensitivity to the drug.
The drug is not used for the treatment of patients with hypercalcemia, hypercalciuria, and severe renal impairment.
Due to the lack of data on safety and efficacy in children under the age of 18 years Osteogenon not use in pediatrics.
The drug should be used with caution in patients suffering from kidney disease and have a tendency to urolithiasis.
Pregnancy:
The drug is not teratogenic, mutagenic and embryotoxic action. The drug can be appointed to the doctor during pregnancy if the expected benefit to the mother is higher than the potential risk to the fetus.
The drug may be assigned during lactation.
Interaction with other drugs:
The drug is not taken together with iron compounds and tetracyclines due to the ability of these compounds form chelate complexes. If necessary, concurrent therapy with these drugs are advised to observe an interval of at least 4 hours between taking these drugs.
The combined application of the drug with vitamin D and thiazide diuretics may develop hypercalcemia.
Overdose:
In applying the drug in doses much higher than the recommended increases the risk of side effects and increases the degree of severity.
Product:
Film-coated tablets, 10 pieces in blister, 4 blisters in a carton box.
Storage conditions:
The drug should be stored in a dry place away from direct sunlight at a temperature of 15 to 25 degrees Celsius.
Shelf life - 4 years.
Composition:
1 tablet contains Osteogenon:
Ossein-hydroxyapatite complex - 830mg;
1 tablet of the drug in the composition of the ossein-hydroxyapatite complex contains 291mg ossein (non-collagenous proteins and peptides - 75mg, collagen proteins - 216m) and 444 mg of hydroxyapatite (calcium - 178mg, phosphorus - 82mg).
Excipients.
Pharmacological group:
Drugs affecting mainly the processes of tissue metabolism
Medicaments containing calcium and potassium
New
New
New
New
New
New
